Zy Therapeutics is pleased to announce its participation in the American Academy of Neurology (AAN) Annual Meeting 2026 in Chicago, one of the leading global forums for advances in neurological science, clinical care, and therapeutic development.
Following a highly successful Scientific Advisory Board convened at AES 2025, which provided strong validation of Kamini’s scientific rationale and clinical development strategy, Zy Therapeutics is continuing to engage with the neurology community to advance its lead program.
KaminiTM is being developed as a potential disease-modifying therapy targeting pathological calcium dysregulation in rare neurological disorders, including Sturge–Weber Syndrome.
At AAN 2026, Zy Therapeutics looks forward to:
- Engaging with key opinion leaders and clinical experts
- Advancing scientific dialogue around disease biology and treatment approaches
- Strengthening relationships within the epilepsy and rare disease communities
Zy Therapeutics is also open to select partnering and collaboration discussions during the meeting.
We look forward to connecting with colleagues, collaborators, and partners in Chicago.
